Persistent Opioid Use Following Resection of Oral Cavity Squamous Cell Carcinoma: Incidence and Risk Factors
Head & Neck · 2026
DOI: 10.1002/hed.70089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2026. Verfasst von Cameron C Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral-Maxillofacial Surgery, University of Maryland Medical Center, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Mouth Neoplasms, Analgesics, Opioid, Carcinoma, Squamous Cell, Postoperative Pain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
Persistent opioid use after head and neck cancer surgery is a growing concern, but data regarding incidence and risk factors remain limited.
Methods
This retrospective cohort study included patients who underwent primary resection of oral cavity squamous cell carcinoma between 2016 and 2022. Preoperative opioid use was classified as naïve, intermittent, or chronic using prescription drug monitoring data. Persistent use was defined as filling an opioid prescription attributed to surgery and two consecutive prescriptions between 120 and 365 days postoperatively. Regression analysis identified independent predictors.
Results
Among 430 subjects, 18.8% met criteria for persistent opioid use. Chronic preoperative use ( p = 0.008), G‐tube persistence at 12 months ( p = 0.041), chronic pain diagnosis ( p = 0.036), and cancer recurrence ( p = 0.021) were independent predictors. Persistent use peaked between 120 and 180 days postoperatively.
Conclusion
Persistent opioid use is common after oral cancer resection and is strongly associated with preoperative opioid use. Early risk stratification may improve outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral-Maxillofacial Surgery, University of Maryland Medical Center, Baltimore, Maryland, USA.
- Department of Otorhinolaryngology, University of Maryland Medical Center, Baltimore, Maryland, USA.
- Department of Medical Oncology, University of Maryland Medical Center, Baltimore, Maryland, USA.
- Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, Maryland, USA.
ORCID-Profile: Jason Molitoris, Matthew Ferris, Jeffrey S Wolf
Zitieren
APA
Lee, C. C., Gandotra, S., Bliss, A., Jenkins, G. W., Dyalram, D., Hatten, K., Moyer, K., Mehra, R., Molitoris, J., Ferris, M., Taylor, R., Wolf, J. S., & Lubek, J. E. (2026). Persistent Opioid Use Following Resection of Oral Cavity Squamous Cell Carcinoma: Incidence and Risk Factors. Head & Neck. https://doi.org/10.1002/hed.70089
Vancouver
Lee CC, Gandotra S, Bliss A, Jenkins GW, Dyalram D, Hatten K, et al. Persistent Opioid Use Following Resection of Oral Cavity Squamous Cell Carcinoma: Incidence and Risk Factors. Head & Neck. 2026. doi:10.1002/hed.70089
BibTeX
@article{Lee2026,
author = {Lee, Cameron C and Gandotra, Sahil and Bliss, Aaron and Jenkins, Glyndwr W and Dyalram, Donita and Hatten, Kyle and Moyer, Kelly and Mehra, Ranee and Molitoris, Jason and Ferris, Matthew and Taylor, Rodney and Wolf, Jeffrey S and Lubek, Joshua E},
title = {Persistent Opioid Use Following Resection of Oral Cavity Squamous Cell Carcinoma: Incidence and Risk Factors},
journal = {Head & Neck},
year = {2026},
doi = {10.1002/hed.70089}
}
EUVIMED